|

Equecabtagene Autoleucel Injection Clinical Trials

2 actively recruiting trials

No change since May 2026

Also known as: FUCASO

Pipeline

Phase 3: 1

Top Sponsors

  • Tongji Hospital1
  • Nanjing IASO Biotechnology Co., Ltd.1

Indications

  • Lupus Nephritis (LN)1
  • Systemic Lupus Erythematosus (SLE)1
  • Lupus1
  • Multiple Myeloma1
  • Cancer1

Other2 trials

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Phase 3
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.